In August the FDA authorized a wearable that does two jobs at once. Abbott\u2019s Libre Duo 10 Day continuously measures glucose and ketones in the fluid under the skin, every minute, for ten days, and sends both to a phone. It is the first device in the United States cleared to track ketones continuously, and the first anywhere cleared to track ketones and glucose together in a single sensor. The population is people with diabetes age 2 and older. The point of the second number is diabetic ketoacidosis \u2014 a metabolic emergency \u2014 not a cleaner reading of breakfast.<\/p>\n\n\n\n
That distinction will not survive contact with the internet. Continuous glucose monitors already escaped the clinic. A parallel consumer market grew around the same hardware for people without diabetes, on the premise that a curve makes food, sleep, and training less abstract. Abbott and Google announced a version of that bet two weeks before the Duo clearance: Lingo, Abbott\u2019s over-the-counter sensor for adults who are not on insulin, which will feed glucose into Google Health later this year so a coach can comment on meals and workouts. Biohackers who already wear a CGM to judge a lunch will treat a ketone trace as the next panel. The clearance is for people who can land in an emergency department if that trace climbs.<\/p>\n\n\n\n
Those are different products from the same company.<\/p>\n\n\n\n
Until Duo, ketone checks were a fingerstick or a urine strip. A single point. No slope. You could be rising into trouble or already coming down and the strip would look the same. Duo measures both analytes in interstitial fluid every minute, day and night, so the phone shows a trace instead of a point. If ketones cross a threshold, the phone alerts. The agency said the clinical file showed the sensor could identify elevated ketones before DKA developed.<\/p>\n\n\n\n
The file is six studies and more than 600 participants, ages 2 and up, across a range of glucose and ketone levels. Breakthrough Device designation came first. Marketing authorization followed on August 25, 2026, through De Novo \u2014 the path for a new type of low- to moderate-risk device. With the authorization the FDA set special controls for labeling and performance testing. Abbott describes a new category on top of that, integrated continuous glucose and ketone monitoring, or iCGK, and says Duo is the first system to meet it.<\/p>\n\n\n\n
The intended user is not \u201canyone curious about ketosis.\u201d It is a person with type 1 or type 2 diabetes who uses insulin or other glucose-lowering drugs, including SGLT2 inhibitors, which can raise ketones even when glucose looks acceptable. That last clause is the clinical reason a dual sensor exists. Euglycemic DKA is the failure mode a glucose-only curve misses. A caregiver gets lead time. A pump company, later, gets a second input. Abbott has said it is working toward automated insulin delivery connections: Beta Bionics\u2019 iLet and Sequel\u2019s twiist by the end of 2026, and Insulet and Tandem in 2027. The sensor sits in the Libre app. U.S. launch was described, at authorization, as later in 2026.<\/p>\n\n\n\n
None of that is a wellness feature. It is a medical device with a ten-day wear, a phone, and an alarm whose job is to fire before an emergency.<\/p>\n\n\n\n
Two weeks earlier, on August 11, Abbott and Google Health announced a different glucose product. Lingo, sold over the counter since 2024 for adults 18 and older who are not using insulin, will, later in 2026, show trends inside the Google Health app next to sleep, activity, and the rest of the consumer file. Google\u2019s Health Coach, which requires a Google Health Premium subscription, is supposed to turn that into advice on food, training, and recovery. Abbott\u2019s own release says it is not intended for medical purposes. The companies also described what Abbott calls one of the largest real-world metabolic health studies to date, combining CGM data with wearable, lab, and survey data to examine links between activity, sleep, wellbeing, and metabolic health.<\/p>\n\n\n\n
That is the consumer land grab. Distribution plus interpretation. Abbott brings a sensor people can buy without a diabetes diagnosis. Google brings the app they already open. My read is that the evidence that intensive glucose tracking helps people without diabetes is still thin. Some users report a clearer link between a meal and an afternoon. Others get a noisy line and a new anxiety. The partnership is, in my read, an attempt to generate better data, and to sell the coach in the meantime.<\/p>\n\n\n\n
Duo and Lingo can share a parent company and still answer different questions. Lingo asks what lunch did to a curve in someone not on insulin. Duo asks whether ketones are climbing in someone whose diabetes treatment can produce a crisis the glucose number will not announce. Putting them in one paragraph without that line is how a press cycle becomes a protocol.<\/p>\n\n\n\n
Ketones already have a consumer mythology. Nutritional ketosis is a diet claim. Exogenous ketones are a supplement claim. A breath meter or a urine strip is a hobby. A continuous interstitial trace, on a phone, looks like the CGM moment all over again: the clinic built the hardware, the internet found a use the label did not write.<\/p>\n\n\n\n
The mechanics encourage the confusion. Both sensors sit on the arm. Both stream to a phone. A person who already pays for Lingo, or for a prescription CGM used off-label to manage a cut, will see Duo and assume the second channel is a better version of the same dashboard. It is not. The alert threshold on a medical ketone sensor is set for danger, not for whether a fast \u201cworked.\u201d A flat ketone line during a low-carb week is not a score. A rising line in a person on an SGLT2 inhibitor can be a reason to stop, check, and call someone.<\/p>\n\n\n\n
The Google deal makes the blur easier. Once glucose is a tile next to steps and sleep, the category story is \u201cmetabolic visibility,\u201d and Duo is metabolic visibility with an emergency attached. My earlier post on Abbott and Google was about the friction between a number and a next action at consumer scale. Duo addresses a different friction: between a rising ketone and a trip that should happen before the emergency department.<\/p>\n\n\n\n
De Novo is not a trophy for accuracy in the abstract. It is permission to market a new type, plus special controls so the next device in the category has a bar. The FDA\u2019s announcement says the studies showed clinically meaningful ketone tracking over ten days, including elevation before DKA. It does not, in the announcement, hand the public a mean absolute relative difference table you can paste next to a Libre 3 glucose spec. Anyone treating Duo as a settled lab instrument should wait for the full performance appendix, not the press quote.<\/p>\n\n\n\n
The labeling itself says as much. The FDA states that ketone information should always be interpreted in the context of glucose readings and symptoms, and Abbott\u2019s own safety information says the Urgent High Ketones alarm may not detect all ketone levels above 3.0 mmol\/L. An alarm with those limits is a safeguard, not a verdict.<\/p>\n\n\n\n
The population limit matters as much as the sensor. Age 2 and up, living with diabetes. Children are included because DKA is a danger in pediatric diabetes, not because a toddler needs a keto score. Adults on insulin or on drugs associated with euglycemic DKA are the other center of the label. A healthy adult running a carnivore week is not the center of the label.<\/p>\n\n\n\n
Pump integration is a promise with a year on it. Abbott expects Beta Bionics iLet and Sequel twiist links by the end of 2026, and Insulet and Tandem links in 2027. Until those links ship, Duo is a monitor and an alert, not a closed loop. Alerts fail in the usual ways: phone on silent, sensor compression, a threshold the user has learned to swipe away. Continuous ketone data will also create a new argument in clinics \u2014 when to act on a slope that used to be a strip in a drawer. That is a protocol problem, not a hardware problem.<\/p>\n\n\n\n
Consumer glucose already taught this market a bad habit. A medical sensor leaves the prescription channel, a coaching app learns to narrate it, and the number becomes a judgment of behavior. Some of that is useful. Some of it is a subscription attached to a curve. Lingo plus Google Health is the current version: an OTC sensor, an AI coach, a study that might later say where the signal is real.<\/p>\n\n\n\n
Duo is the other Abbott. Same interstitial fluid. Same minute-by-minute habit. Different job. The second analyte is there because glucose-only monitoring has a known blind spot, and because the cost of missing it is an ICU, not a disappointing workout. Biohackers will still wear it if they can get it. Forums will still post screenshots of ketone traces next to macros. That does not change the clearance.<\/p>\n\n\n\n
A number that flags a medical emergency is not the same product as a number that judges your lunch. Abbott is bringing both to market. The useful reading is to keep them apart: one sensor for a crisis the glucose line can hide, one sensor for a consumer experiment that has not yet earned a clinical claim. Mix the labels and you get the usual wearable ending \u2014 a precise trace, an overconfident caption, and a person who thought the alarm was a score.<\/p>\n\n\n\n
Avanti. Measure what matters.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" In August the FDA authorized a wearable that does two jobs at once. Abbott\u2019s Libre Duo 10 Day continuously measures glucose and ketones in the fluid under the skin, every minute, for ten days, and sends both to a phone. It is the first device in the United States cleared…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3952","post","type-post","status-publish","format-standard","hentry","category-1"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.effgen.us\/index.php?rest_route=\/wp\/v2\/posts\/3952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.effgen.us\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.effgen.us\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.effgen.us\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.effgen.us\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3952"}],"version-history":[{"count":1,"href":"https:\/\/www.effgen.us\/index.php?rest_route=\/wp\/v2\/posts\/3952\/revisions"}],"predecessor-version":[{"id":3953,"href":"https:\/\/www.effgen.us\/index.php?rest_route=\/wp\/v2\/posts\/3952\/revisions\/3953"}],"wp:attachment":[{"href":"https:\/\/www.effgen.us\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.effgen.us\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.effgen.us\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}